Jefferson James W
University of Wisconsin School of Medicine & Public Health, Madison Institute of Medicine, Inc., 7617 Mineral Point Road, Suite 300, Madison, WI 53717, USA.
Expert Rev Neurother. 2008 May;8(5):715-22. doi: 10.1586/14737175.8.5.715.
Bupropion is an antidepressant thought to work through effects on norepinephrine and dopamine. It was first marketed in the USA in 1989 as a thrice-daily immediate-release preparation. This was followed in 1996 by twice-daily sustained-release and, most recently in 2003, by once-daily extended-release preparations. Its clinical efficacy for treating depression is equivalent to that of other antidepressants. In addition, the extended-release preparation has been shown to be effective for treating geriatric depression and depression characterized by reduced energy, pleasure and interest, and for preventing recurrence of seasonal affective disorder. Favorable aspects of its side-effect profile include low likelihood of somnolence, sexual dysfunction and weight gain. This review provides a history of the evolution of bupropion in its three formulations, with an emphasis on the efficacy and tolerability of the extended-release preparation.
安非他酮是一种抗抑郁药，其作用机制被认为是通过影响去甲肾上腺素和多巴胺来实现的。它于1989年在美国首次上市，为每日三次的速释制剂。1996年推出了每日两次的缓释制剂，最近在2003年又推出了每日一次的长效释放制剂。其治疗抑郁症的临床疗效与其他抗抑郁药相当。此外，长效释放制剂已被证明对治疗老年抑郁症以及以精力、愉悦感和兴趣降低为特征的抑郁症有效，还可预防季节性情感障碍的复发。其副作用方面的有利之处包括嗜睡、性功能障碍和体重增加的可能性较低。本综述介绍了安非他酮三种制剂的演变历史，重点阐述了长效释放制剂的疗效和耐受性。
